

Vaccine developer enters company growth phase

- Verovaccines completes the validation of its vaccine and manufacturing platforms.
- Company to focus now on development to bring new vaccines to market quickly. Another swine vaccine enters pipeline.

Halle (Saale), Germany, July 11, 2023 – For the German vaccine specialist Verovaccines, all technological prerequisites are now in place to enter a new phase of the company's development. During the validation phase both technology platforms have been significantly de-risked:

The Unified Vaccine Platform has been validated *in vivo* regarding vaccine combination, usability with different species/indications and dose requirements.

The Unified Manufacturing Platform was intensively evaluated regarding reproducibility with various vaccine strains, yielding the concept of a “same-for-all” manufacturing platform for *K. lactis*-based vaccines. In addition, the production process was scaled up to industrial scale at two independent service providers and thus also validated. These results provided a first estimate of the production costs of *K. lactis*-based vaccines, which are about 10- to 20-fold lower compared to benchmark technologies for a porcine vaccine.



Freeze-dried recombinant yeast as the basis for highly potent subunit vaccines. Following the validation of its new vaccine and manufacturing platforms, Verovaccines is expanding its portfolio with new mono- and combination vaccines to develop highly competitive vaccines for the market.

© Thomas Meinicke

Managing Director Dr. Hanjo Hennemann: “We have recently completed a number of extensive validation and risk mitigation studies on both platforms. This means that we can now focus on developing vaccines to bring them to market rapidly. The upscaling studies have

progressed to the point where we can manufacture our most advanced development candidate in a GMP facility for reproducible production at industrial scale.” Prof. Dr. Sven-Erik Behrens, CSO, added: “We have initiated this growth phase by nominating another program for development of a second wholly owned porcine vaccine. This program has already reached the prototype stage of the vaccine with several candidates.”

Verovaccines is currently evaluating different strategic options to support the company’s growth path and bring its new vaccines to market as quickly as possible.

###

About VEROVACCiNES GmbH

Verovaccines was spun off from Martin Luther University Halle-Wittenberg by professor Sven-Erik Behrens, Ph.D., Hanjo Hennemann, Ph.D. and Martina Behrens, DVM. In addition to its experienced founders, the company has a staff of scientists with expertise in virology, molecular biology, veterinary medicine, process development and project management. Verovaccines has a pipeline of six proprietary vaccines programs, and another vaccine program with a Japanese pharmaceutical company. Six of these programs achieved *proof-of-concept* in the target animal.

About the proprietary yeast-based vaccine and production platforms

Verovaccines’ vaccines are based on a proprietary and patented technology platform using the lactic yeast *Kluyveromyces lactis*. Its Unified Vaccine Platform can be used against a broad spectrum of pathogens, enables easy combination of vaccines, significantly shortens development times compared to classical vaccines, and has been de-risked through multiple *proof-of-concept* studies in target animals. The Unified Manufacturing Platform offers same-for-all functionality with short production cycle times and exceptionally low costs. Verovaccines is currently using its technology to develop a product pipeline of subunit marker vaccines against pathogens in swine, cattle and poultry.

Contact us:

VEROVACCiNES GmbH
Mareike Schünemann
Blücherstrasse 26
06120 Halle (Saale), Germany
E-mail: info@verovaccines.com
Web: www.verovaccines.com

